References
L. Li, Y.H. Dong, Y. Bai, Z.Y. Tang, Y.M. Deng, Z. Wu et al. Association of sglt2is with cardiovascular and reproductive diseases: a meta-analysis based on 14 large-scale randomized trials. Endocrine. 2023. https://doi.org/10.1007/s12020-023-03618-x.
M. Qiu, L.L. Ding, Z.L. Zhan, S.Y. Liu, Use of sglt2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of sglt2 inhibitors. Endocrine 73(1), 31–36 (2021). https://doi.org/10.1007/s12020-021-02644-x
A. Kang, B. Smyth, B.L. Neuen, H. Heerspink, G.L. Di Tanna H. Zhang et al. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the canvas program and credence randomized double-blind trials. Diabetes Obes. Metab. 25(8), 2151–2162 (2023). https://doi.org/10.1111/dom.15091
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Xiao, Y., Peng, S. & Liu, C. Association of SGLT2is with respiratory and skin diseases. Endocrine (2024). https://doi.org/10.1007/s12020-024-03739-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12020-024-03739-x